Ligand Pharmaceuticals Inc (Ligand) develops and acquires technologies, including antibody discovery technologies, ion channel discovery technology, formulation science, pseudomonas fluorescent protein expression technology, and liver-targeted pro-drug technologies that help pharmaceutical and biotechnology companies in the discovery and development of medicines. The company operates through one reportable segment, the development and licensing of biopharmaceutical assets.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Ligand has developed a diverse portfolio through research and acquisitions, focusing on a wide range of underlying technologies. This diversification allows the company to benefit from exposure to a broader spectrum of scientific innovation, increased licensing opportunities, and reduced impact from individual patent expirations. The company has established major technology alliances with partners such as Merck, Amgen, and Sanofi, contributing to its robust pipeline. Some of its pipeline products include BOT/BAL in Phase 2 under the Oncology therapy area, D-Fi in Phase 3 under the Rare Disease therapy area, Ensifentrine in Phase 2 under the Respiratory Disease therapy area, QTORIN rapamycin 3.9% in Phase 3 under the Rare Disease therapy area, Lasofoxifene in Phase 3 under the Oncology therapy area, Sparsentan in Phase 3 under the Kidney Disease therapy area, and VK2809 in Phase 2 under the Hepatology therapy area. Other pipeline products include ACLX-001, ACLX-002, ANEB-001, CE-furosemide, CE-Meloxicam, Frovatriptan, MB07133, NEXTERONE, Pradefovir, SESQUIENT, Vilazodone, and Voriconazole, among others. In FY2024, the company spent US$21.4 million on R&D, which as a percentage of revenue, stood at 12.8% and declined 12.7% YoY.